Languages

Blog

New Research Funding for LUNIRI
2018-08-21

Steffen Frese, the founder of LUNIRI, received new research funding from the German Research Foundation. http://gepris.dfg.de/gepris/projekt/317392477?language=en Research will be conducted at the German Rheumatism Research Centre in Berlin, Germany.&nb ... Read More

Berlin Marathon 2017
Running for lupus. Running for the new treatment.     2017-09-27

LUNIRI in the News
Lupus Nephritis and Irinotecan at LUPUSNEWSTODAY.COM     2016-11-30

http://lupusnewstoday.com/2016/11/11/irinotecan-topo-1-blocker-seen-as-potential-lupus-specific-treatment

Neue Ergebnisse aus der Forschung veröffentlich in Arthritis Research & Therapy
Wir konnten zeigen, dass Irinotecan in einem zweiten Model von spontaner Lupuserkrankung sowohl die Nieren- als auch die Hautbeteiligung effektiv unterdrückt.     2016-10-25

Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan. Arthritis Res Ther. 2016 Oct 22; 18(1):243

New scientific data published in Arthritis Research & Therapy
Irinotecan efficiently suppressed both lupus nephritis and skin lesions in a second and genetically different model of spontaneous SLE     2016-10-25

Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan. Arthritis Res Ther. 2016 Oct 22; 18(1):243

Cancelation of credit card payment
2016-05-27

Due to the absence of donations for LUNIRI in the context of monthly operating costs, transfer of donation by credit card will be canceled from 1st of June 2016. We deeply regret this development.

More Blog Entries

Publikationen

 

  Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan  Andreas Keil, Sean R. Hall, Meike Körner, Martin Herrmann, Ralph A. Schmid and Steffen Frese  Arthritis Research & Therapy, 2016 Oct 22. 18(1): 243    DOI: 10.1186/s13075-016-1144-5               http://www.ncbi.nlm.nih.gov/pubmed/27770825

  The topoisomerase I inhibitor irinotecan and the tyrosyl-DNA phosphodiesterase 1 inhibitor furamidine synergistically suppress murine lupus nephritis  Andreas Keil, Manuela Frese-Schaper, Selina K. Steiner, Meike Körner, Ralph A. Schmid and Steffen Frese  Arthritis & Rheumatology, 2015 Mar 16. doi: 10.1002/art.39119  http://www.ncbi.nlm.nih.gov/pubmed/25779651

 Low-Dose Irinotecan Improves Advanced Lupus Nephritis in MicePotentially by Changing DNA Relaxation and Anti–Double–Stranded DNA Binding  Manuela Frese-Schaper, Andreas Keil, Selina K. Steiner, Mathias Gugger, Meike Körner, Gregor J. Kocher, Lena Schiffer, Hans-Joachim Anders, Uyen Huynh-Do, Ralph A. Schmid and Steffen Frese. Arthritis & Rheumatology, Vol. 66, No. 8, August 2014, pp 2259–2269, DOI 10.1002/art.38665 – www.ncbi.nlm.nih.gov/pubmed/24729466,   Supplement

  Structural modification of DNA – a therapeutic option in SLE?        Steffen Frese and Betty Diamond. Nature Reviews Rheumatology, Volume 7, Dec 2011 - http://www.ncbi.nlm.nih.gov/pubmed/22009329

  Reversal of Established Lupus Nephritis and Prolonged Survival of New Zealand Black x New Zealand White Mice Treated with the Topoisomerase I Inhibitor Irinotecan, Manuela Frese-Schaper, Jakob Zbaeren, Mathias Gugger, Marc Monestier, and Steffen Frese. The Journal of Immunology, February 15, 2010 Vol. 184 No. 4 2175-2182, DOI: 10.4049/​jimmunol.0903153 – http://www.ncbi.nlm.nih.gov/pubmed/20083657